PLSE insider buying and SEC filings, explained
Pulse Biosciences, Inc. · CIK 1625101
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$13.5M
Insiders who bought
3
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$2.9M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Aug 31–Sep 1, 2026 | Open-market purchase | Liane Rae Teplitsky (President / COO) bought 2,025 shares between Aug 31 and Sep 1 at about $49.37 ($100K) in an open-market purchase. Holdings up 98% to 4,095 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 2, 2026 |
| Aug 26–28, 2026 | Open-market purchase | Liane Rae Teplitsky (President / COO) bought 2,070 shares between Aug 26 and Aug 28 at about $48.29 ($100K) in an open-market purchase. New position of 2,070 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 28, 2026 |
| May 11, 2026 | Purchase (code P) Amended filing | Robert W. Duggan (Director and 10% owner) bought 660,233 shares at $19.69 ($13.0M), reported as a purchase (code P). Holdings up 1% to 48,370,047 shares. Not marked as a 10b5-1 plan trade. This amends a filing from May 11. | SEC filing Filed May 15, 2026 |
| May 11, 2026 | Purchase (code P) Amended filing | Paul A. Laviolette (CEO and Director) bought 15,000 shares at $19.69 ($295K), reported as a purchase (code P). Holdings up 999%+ to 15,846 shares. Not marked as a 10b5-1 plan trade. This amends a filing from May 11. | SEC filing Filed May 11, 2026 |
| Feb 18, 2026 | Planned (10b5-1) | Kevin Patrick Danahy (Chief Commercial Officer) sold 5,000 shares at about $23.64 ($118K), marked as a 10b5-1 plan trade. Holdings down 10% to 43,298 shares. | SEC filing Filed Feb 23, 2026 |
| Feb 12–17, 2026 | Planned (10b5-1) | Kevin Patrick Danahy (Chief Commercial Officer) sold 60,000 shares between Feb 12 and Feb 17 at about $23.51 ($1.4M), marked as a 10b5-1 plan trade. Holdings down 58% to 43,298 shares. | SEC filing Filed Feb 17, 2026 |
| Feb 9–11, 2026 | Planned (10b5-1) | Kevin Patrick Danahy (Chief Commercial Officer) sold 60,000 shares between Feb 9 and Feb 11 at about $23.39 ($1.4M), marked as a 10b5-1 plan trade. Holdings down 58% to 43,298 shares. | SEC filing Filed Feb 11, 2026 |
12 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
2 insiders bought in 30 days
$13.3M in purchases since May 11, 2026 · Purchases traded May 11, 2026 to May 11, 2026 · Closed
| Insider | Value | Traded | Source |
|---|---|---|---|
| Paul A. Laviolette (CEO) | $295K | May 11, 2026 | SEC filing |
| Robert W. Duggan (Director) | $13.0M | May 11, 2026 | SEC filing |
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow PLSE in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.